Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphoma

NCT05487495 | Withdrawn Phase 1 DMC

• 1 other identifier: BRYY-IIT-LCYJ-2022-026
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

This is a FIH, single center, open label, non-randomized, single-arm, Phase I clinical trial to evaluate the safety and tolerability of CD5 CAR T (CT125B) cells in subjects with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma. 9-18 subjects will be enrolled. After the collection of PBMC and about 5 days before infusion, lymphodepletion (fludarabine at 30 mg/m\^2/day and cyclophosphamide at 250 mg/m\^2/day; for prior-SCT donor-derived CAR T-cell infusion) or intensified lymphodepletion (fludarabine at 30 mg/m\^2/day and cyclophosphamide at 30 mg/kg/day; for new donor-derived CAR T-cell infusion) will be administrated for 3 days. Then this study will be using BOIN1/2 approach from starting dose 1: 1×10\^6 (±20%) to dose 2: 2×10\^6 (±20%). If the manufactured cells were not sufficient to meet the preassigned standard dose criteria, patients are given infusion at a low dose of 5×10\^5 (±20%) /kg.

Conditions

T-Cell Acute Lymphoblastic Leukemia/Lymphoma

Keywords

CAR-T; Leukemia; acute lymphoblastic leukemia/lymphoma

Outcome Measures

Primary Outcomes (2)

• Incidence and type of dose-limiting toxicity (DLT)

  DLT assessment according to the clinical study protocol.

  21 days post intravenous injection

• Incidence and severity of adverse events (AE)

  Incidence and severity of adverse events as assessed by NCI-CTCAE 5.0.

  30 days post intravenous injection

Secondary Outcomes (5)

• Objective response rate (ORR)

  30 days post infusion

• Counts and persistence of CAR T cells

  30 days post infusion

• Incidence and grade of severe adverse events (SAEs)

  2 years post infusion

• Best overall response (BOR) rate

  3 months post infusion

• The counts of CART cells after using CAR T suicidal switch drugs .

  7 days post administration of ganciclovir

Study Arms (1)

CD5 CAR T (CT125B)

EXPERIMENTAL

All patients who receive CD5 CAR T (CT125B) cell infusion.

Biological: CD5 CAR T (CT125B)

Interventions

CD5 CAR T (CT125B) BIOLOGICAL

Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: After the collection of PBMC and about 5 days before infusion, lymphodepletion (fludarabine at 30 mg/m\^2/day and cyclophosphamide at 250 mg/m\^2/day; for prior-SCT donor-derived CAR T-cell infusion) or intensified lymphodepletion (fludarabine at 30 mg/m\^2/day and cyclophosphamide at 30 mg/kg/day; for new donor-derived CAR T-cell infusion) will be administrated for 3 days.

CD5 CAR T (CT125B)

Eligibility Criteria

• Age: 1 Year - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• In order to be eligible to participate in this study, an individual must meet all of the following criteria:
• Candidates with relapsed or refractory CD5+ T cell acute lymphoblastic leukemia/lymphoma, who have progressed after treatment with all standard therapies or been intolerant of standard care, have limited prognosis with currently available therapies and had no available curative treatment options (such as SCT or chemotherapy)
• Male or female, aged 1-70 years
• No serious allergic constitution
• Eastern Cooperative Oncology Group (ECOG) performance status (Oken et al., 1982) score 0 to 2
• Have life expectancy of at least 60 days based on investigator's judgement
• CD5 positive on blasts in bone marrow or CSF by flow cytometry, or CD5 positive on tumor tissues by immunohistochemistry; (CD5 positive criteria: Flow cytometry: Positive: \> 80% of tumor cells expressed CD5 and the mean fluorescence intensity (MFI) of CD5 is the same as that in normal T cells; Dim: \> 80% of tumor cells expressed CD5, but the MFI of CD5 is lower than that in normal T cells as least as 1 log; Partial positive: 20-80% of tumor cells expressed CD5 and the MFI of CD5 is the same as that in normal T cells. Tumor tissue immunohistochemistry: Positive \> 30% tumor cells expressed CD5)
• Provide a signed informed consent before any screening procedure. Patients who voluntarily participate in the study should have the ability to understand and sign the informed consent form (ICF) and be willing to follow the visit schedule and relevant study procedure, as specified in the protocol. Candidates aged 19-70 years old need to be sufficiently conscious and able to sign the treatment consent form and voluntary consent form. Candidates of 8-18 years old need to be sufficiently conscious and able to sign the treatment consent form and voluntary consent form, besides, their legal guardian or patient advocate also need to sign the treatment consent form and voluntary consent form. Children candidates of 1-7 years old can be recruited after the legal guardian or patient advocate need to sign the treatment consent form and voluntary consent form.
• Have suitable and available allogeneic hematopoietic stem cell transplantation donor, and is willing to proceed to SCT if achieve CR.

You may not qualify if:

• An individual who meets any of the following criteria will be excluded from participation in this study:
• Intracranial hypertension or disorder of consciousness
• Symptomatic heart failure or severe arrhythmia
• Symptoms of severe respiratory failure
• Complicated with other types of malignant tumors
• Diffuse intravascular coagulation
• Serum creatinine and / or blood urea nitrogen ≥ 1.5 times of the normal value
• Suffering from septicemia or other uncontrollable infections
• Patients with uncontrollable diabetes
• Severe mental disorders
• Obvious and active intracranial lesions were detected by cranial magnetic resonance imaging (MRI)
• Have received organ transplantation (excluding bone marrow transplant)
• Reproductive-aged female patients with positive blood HCG test
• Screened to be positive of infection of hepatitis (including hepatitis B and C), AIDS or syphilis
• Post-CAR SCT is not feasible in patients

Sponsors & Collaborators

• Beijing Boren Hospital: lead

Study Sites (1)

Beijing Gaobo Boren Hospital

Beijing, Beijing Municipality, 100070, China

Location

MeSH Terms

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma; Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma

Condition Hierarchy (Ancestors)

Leukemia, Lymphoid; Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Study Officials

• Jing Pan, MD/PhD

  Beijing Gaobo Boren Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 1, 2022
• First Posted: August 4, 2022
• Study Start: August 3, 2022
• Primary Completion: December 31, 2023
• Study Completion: December 31, 2023
• Last Updated: November 14, 2024

Record last verified: 2022-08

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)